These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37546576)

  • 21. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New business models for antibiotic innovation.
    So AD; Shah TA
    Ups J Med Sci; 2014 May; 119(2):176-80. PubMed ID: 24646116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory Incentives for Antibiotic Drug Development: A Review of Recent Proposals.
    Sinha MS; Kesselheim AS
    Bioorg Med Chem; 2016 Dec; 24(24):6446-6451. PubMed ID: 27591793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
    Towse A; Hoyle CK; Goodall J; Hirsch M; Mestre-Ferrandiz J; Rex JH
    Health Policy; 2017 Oct; 121(10):1025-1030. PubMed ID: 28888660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH; Mohr JF
    Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics.
    Renwick MJ; Brogan DM; Mossialos E
    J Antibiot (Tokyo); 2016 Feb; 69(2):73-88. PubMed ID: 26464014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (Inter)nationalising the antibiotic research and development pipeline.
    Singer AC; Kirchhelle C; Roberts AP
    Lancet Infect Dis; 2020 Feb; 20(2):e54-e62. PubMed ID: 31753765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future.
    Ohashi T; Nagashima M; Kawai N; Ohmagari N; Tateda K
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1603-1614. PubMed ID: 36368311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward.
    Wasan H; Singh D; Reeta KH; Gupta YK
    Biology (Basel); 2023 Jan; 12(1):. PubMed ID: 36671792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access and Innovation.
    Årdal C; Lacotte Y; Edwards S; Ploy MC; On Behalf Of The European Union Joint Action On Antimicrobial Resistance And Healthcare-Associated Infections Eu-Jamrai
    Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34205554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development.
    Theuretzbacher U; Årdal C; Harbarth S
    Infect Dis Rep; 2017 Mar; 9(1):6836. PubMed ID: 28458797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.
    Gigante V; Alm RA; Melchiorri D; Rocke T; Arias CA; Czaplewski L; Fernandes P; Franceschi F; Harbarth S; Kozlov R; Lienhardt C; Ohmagari N; Ogilvie LA; Paul M; Rex JH; Silver LL; Spigelman M; Sati H; Cameron AM
    Antimicrob Agents Chemother; 2024 Aug; 68(8):e0053524. PubMed ID: 39007560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advancing global antibiotic research, development and access.
    Piddock LJV; Alimi Y; Anderson J; de Felice D; Moore CE; Røttingen JA; Skinner H; Beyer P
    Nat Med; 2024 Sep; 30(9):2432-2443. PubMed ID: 39227444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of hospital acquired infections and antimicrobial resistance in Europe: the way to go.
    Friedrich AW
    Wien Med Wochenschr; 2019 Feb; 169(Suppl 1):25-30. PubMed ID: 30623278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Horizon Europe, research and innovation programme until 2027 - what is new comparing with Horizon 2020?
    Kinkorová J
    Cas Lek Cesk; 2022; 161(3-4):163-166. PubMed ID: 36100458
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.